Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Prostate Cancer | Research article

First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis

Authors: Zheng-Ju Ren, De-Hong Cao, Qin Zhang, Peng-Wei Ren, Liang-Ren Liu, Qiang Wei, Wu-Ran Wei, Qiang Dong

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The relationship between first-degree family history of female breast cancer and prostate cancer risk in the general population remains unclear. We performed a meta-analysis to determine the association between first-degree family history of female breast cancer and prostate cancer risk.

Methods

Databases, including MEDLINE, Embase, and Web of Science, were searched for all associated studies that evaluated associations between first-degree family history of female breast cancer and prostate cancer risk up to December 31, 2018. Information on study characteristics and outcomes were extracted based on the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. The quality of evidence was assessed using the GRADE approach.

Results

Eighteen studies involving 17,004,892 individuals were included in the meta-analysis. Compared with no family history of female breast cancer, history of female breast cancer in first-degree relatives was associated with an increased risk of prostate cancer [relative risk (RR) 1.18, 95% confidence interval (CI) 1.12–1.25] with moderate-quality evidence. A history of breast cancer in mothers only (RR 1.19, 95% CI 1.10–1.28) and sisters only (RR 1.71, 95% CI 1.43–2.04) was associated with increased prostate cancer risk with moderate-quality evidence. However, a family history of breast cancer in daughters only was not associated with prostate cancer incidence (RR 1.74, 95% CI 0.74–4.12) with moderate-quality evidence. A family history of female breast cancer in first-degree relatives was associated with an 18% increased risk of lethal prostate cancer (95% CI 1.04–1.34) with low-quality evidence.

Conclusions

This review demonstrates that men with a family history of female breast cancer in first-degree relatives had an increased risk of prostate cancer, including risk of lethal prostate cancer. These findings may guide screening, earlier detection, and treatment of men with a family history of female breast cancer in first-degree relatives.
Literature
1.
Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic markers in prostate Cancer decision making. Eur Urol. 2018;73(4):572–82.PubMedCrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
3.
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484–92.PubMedPubMedCentralCrossRef
4.
5.
Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377–85.PubMedCrossRef
6.
Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, Albright LA. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75(4):390–8.PubMedCrossRef
7.
Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012;30(2):143–8.PubMedCrossRef
8.
Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One. 2011;6(10):e27130.PubMedPubMedCentralCrossRef
9.
Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385–91 391e381-382.PubMedCrossRef
10.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.PubMedCrossRef
11.
Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–59.PubMedCrossRef
12.
O’Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6):961–7.PubMedCrossRef
13.
Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105(8):1230–4.PubMedPubMedCentralCrossRef
14.
Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697–701.PubMedPubMedCentralCrossRef
15.
Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748–57.PubMedPubMedCentralCrossRef
16.
Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, et al. Germline mutations in ATM and BRCA1/2 are associated with Grade reclassification in men on active surveillance for prostate Cancer. Eur Urol. 2018.
17.
Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate Cancer and are associated with early age at death. Eur Urol. 2017;71(5):740–7.PubMedCrossRef
18.
Hemminki K, Sundquist J. Brandt a:do discordant cancers share familial susceptibility? Eur J Cancer. 2012;48(8):1200–7.PubMedCrossRef
19.
Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, Giovannucci E, Parmigiani G, Mucci LA. Family history of breast or prostate Cancer and prostate Cancer risk. Clin Cancer Res. 2018;24(23):5910–7.PubMedPubMedCentralCrossRef
20.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
21.
Frank C, Sundquist J, Hemminki A, Hemminki K. Familial associations between prostate Cancer and other cancers. Eur Urol. 2017;71(2):162–5.PubMedCrossRef
22.
McCAHY PJ, HARRIS CA, NEAL DE. Breast and prostate cancer in the relatives of men with prostate cancer. Br J Urol. 1996;78:552–6.PubMedCrossRef
23.
Lamy PJ, Tretarre B, Rebillard X, Sanchez M, Cenee S, Menegaux F. Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study. Oncotarget. 2018;9(34):23661–9.PubMedPubMedCentralCrossRef
24.
Thomas JA 2nd, Gerber L, Moreira DM, Hamilton RJ, Banez LL, Castro-Santamaria R, Andriole GL, Isaacs WB, Xu J, Freedland SJ. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med. 2012;272(1):85–92.PubMedPubMedCentralCrossRef
25.
Mori M, Masumori N, Fukuta F, Nagata Y, Sonoda T, Miyanaga N, Akaza H, Tsukamoto T. Weight gain and family history of prostate or breast cancers as risk factors for prostate cancer: results of a case-control study in Japan. Asian Pac J Cancer Prev. 2011;12(3):743–7.PubMed
26.
Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate. 2008;68(14):1582–91.PubMedPubMedCentralCrossRef
27.
Beebe-Dimmer JL, Drake EA, Dunn RL, Bock CH, Montie JE, Cooney KA. Association between family history of prostate and breast cancer among African-American men with prostate cancer. Urology. 2006;68(5):1072–6.PubMedCrossRef
28.
Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ (Clinical research ed). 1992;305(6858):855–7.CrossRef
29.
Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86(21):1600–8.PubMedCrossRef
30.
Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwartz AG, Swanson GM, Silverman DT, Brown LM, Hoover RN, et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer. 1995;60(3):361–4.PubMedCrossRef
31.
Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst. 1995;87(13):991–6.PubMedCrossRef
32.
Glover FE Jr, Coffey DS, Douglas LL, Russell H, Cadigan M, Tulloch T, Wedderburn K, Wan RL, Baker TD, Walsh PC. Familial study of prostate cancer in Jamaica. Urology. 1998;52(3):441–3.PubMedCrossRef
33.
Kalish LA, McDougal WS, McKinlay JB. Family history and the risk of prostate cancer. Urology. 2000;56(5):803–6.PubMedCrossRef
34.
Bai Y, Gao YT, Deng J, Sesterhenn IA, Fraumeni JF, Hsing AW. Risk of prostate cancer and family history of cancer: a population-based study in China. Prostate Cancer Prostatic Dis. 2005;8(1):60–5.PubMedCrossRef
35.
Negri E, Pelucchi C, Talamini R, Montella M, Gallus S, Bosetti C, Franceschi S, La Vecchia C. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. Int J Cancer. 2005;114(4):648–52.PubMedCrossRef
36.
Suzuki T, Matsuo K, Wakai K, Hiraki A, Hirose K, Sato S, Ueda R, Tajima K. Effect of familial history and smoking on common cancer risks in Japan. Cancer. 2007;109(10):2116–23.PubMedCrossRef
37.
Rodríguez C, Calle EE, Tatham LM, Wingo PA, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Family history of breast Cancer as a predictor for fatal prostate Cancer. Epidemiology. 1998;9(5):525–9.PubMedCrossRef
38.
Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, Pukkala E, Christensen K, Adami HO, Holm NV, et al. The heritability of prostate cancer in the Nordic twin study of Cancer. Cancer Epidemiol Biomark Prev. 2014;23(11):2303–10.CrossRef
39.
Romero FR, Romero AW, Almeida RM, Oliveira FC Jr, Tambara Filho R. The significance of biological, environmental, and social risk factors for prostate cancer in a cohort study in Brazil. Int Braz J Urol. 2012;38(6):769–78.PubMedCrossRef
40.
Tse LA, Lee PMY, Ho WM, Lam AT, Lee MK, Ng SSM, He Y, Leung KS, Hartle JC, Hu H, et al. Bisphenol a and other environmental risk factors for prostate cancer in Hong Kong. Environ Int. 2017;107:1–7.PubMedCrossRef
41.
Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK. Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol. 2015;193(1):75–9.PubMedCrossRef
42.
Perez-Cornago A, Key TJ, Allen NE, Fensom GK, Bradbury KE, Martin RM, Travis RC. Prospective investigation of risk factors for prostate cancer in the UK biobank cohort study. Br J Cancer. 2017;117(10):1562–71.PubMedPubMedCentralCrossRef
43.
Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107(5):797–803.PubMedCrossRef
44.
Palmero EI, Alemar B, Schuler-Faccini L, Hainaut P, Moreira-Filho CA, Ewald IP, Santos PK, Ribeiro PL, Oliveira CB, Calvez-Kelm FL, et al. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from southern Brazil. Genet Mol Biol. 2016;39(2):210–22.PubMedPubMedCentralCrossRef
45.
Peixoto A, Santos C, Pinto P, Pinheiro M, Rocha P, Pinto C, Bizarro S, Veiga I, Principe AS, Maia S, et al. The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. Clin Genet. 2015;88(1):41–8.PubMedCrossRef
46.
Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S. Implications of high rates of metastatic prostate Cancer in BRCA2 mutation carriers. Prostate. 2016;76(13):1135–45.PubMedPubMedCentralCrossRef
47.
Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate Cancer. Eur Urol. 2016;69(6):992–5.PubMedCrossRef
48.
Song WH, Kim SH, Joung JY, Park WS, Seo HK, Chung J, Lee KH. Prostate Cancer in a patient with a family history of BRCA mutation: a case report and literature review. J Korean Med Sci. 2017;32(2):377–81.PubMedCrossRef
49.
Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10):1116–21.PubMedPubMedCentralCrossRef
50.
Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ, et al. Genome-wide meta-analyses of breast, ovarian, and prostate Cancer association studies identify multiple new susceptibility loci shared by at least two Cancer types. Cancer Discov. 2016;6(9):1052–67.PubMedPubMedCentralCrossRef
Metadata
Title
First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis
Authors
Zheng-Ju Ren
De-Hong Cao
Qin Zhang
Peng-Wei Ren
Liang-Ren Liu
Qiang Wei
Wu-Ran Wei
Qiang Dong
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6055-9

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes

Review

Challenges of driving CD30-directed CAR-T cells to the clinic

Research article

Establishing of mouse oral carcinoma cell lines derived from transgenic mice and their use as syngeneic tumorigenesis models

Research article

Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines

Research article

Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

Research article

Knockdown of estrogen receptor β increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits